2-羟基雌三醇 | 47199-64-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 2-羟基雌三醇
• 英文名称: 2,16alpha-Dihydroxyestradiol
• 英文别名: 2-hydroxyestriol；(8R,9S,13S,14S,16R,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-2,3,16,17-tetrol
• CAS: 47199-64-4；1232-80-0
• 化学式: C₁₈H₂₄O₄
• mdl: MFCD00056550
• 分子量: 304.386
• InChiKey: ZUGCDOZAVASBQT-SLVREZFOSA-N

物化性质

• 熔点：
  >248°C (dec.)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  80.9
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-羟基雌三醇 在 potassium carbonate 、 三乙胺 作用下， 以 正己烷 、 水 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  A novel GC-MS method in urinary estrogen analysis from postmenopausal women with osteoporosis

  摘要：

  Estrogen metabolites play important roles in the development of female-related disorders and homeostasis of the bone. To improve detectability, a validated gas chromatography-mass spectrometry (GC-MS) method was conducted with two-phase extractive ethoxycarbonlyation (EOC) and subsequent pentafluoropropionyl (PFP) derivatization was introduced. The resulting samples were separated through a high-temperature MXT-1 column within an 8 min run and were detected in the selected ion monitoring (SIM) mode. The optimized analytical conditions led to good separation with a symmetric peak shape for 19 estrogens as their EOC-PFP derivatives. The limit of quantification (LOQ) was from 0.02 to similar to 0.1 ng/ml for most estrogens analyzed, except for 2-hydroxyestriol (0.5 ng/ml). The devised method was found to be linear (r(2) > 0.995) in the range from the LOQ to 40 ng/ml, whereas the precision (% CV) and accuracy (% bias) ranged from 1.4 to 10.5% and from 91.4 to 108.5%, respectively. The good sensitivity and selectivity of this method even allowed quantification of the estrogen metabolites in urine samples obtained from the postmenopausal female patients with osteoporosis. The present technique can be useful for clinical diagnosis as well as to better understand the pathogenesis of estrogen-related disorders in low-level quantification.-Moon, J-Y., K. J. Kim, M. H. Moon, B. C. Chung, and M. H. Choi. A novel GC-MS method in urinary estrogen analysis from postmenopausal women with osteoporosis. J. Lipid Res. 2011. 52: 1595-1603.

  DOI：

  10.1194/jlr.d016113
• 作为产物：
  描述：

  雌三醇 16,17-二乙酸酯 在 硝酸 、 sodium nitrite 作用下， 生成 2-羟基雌三醇
  参考文献：
  名称：

  Convenient large scale preparation of catechol estrogens

  摘要：

  2-Hydroxyestrone, 2-hydroxyestradiol-17beta, 2-hydroxy-17alpha-ethynylestradiol, 2-hydroxyestriol, 4-hydroxyestrone, 4-hydroxyestradiol-17beta, 4-hydroxy-17alpha-ethynylestradiol and 4-hydroxyestriol are prepared on a preparative scale from the corresponding aminophenols using a new inverse oxidation procedure. By the synthesis described both the 2- and 4-hydroxylated estrogens are available in high yields.

  DOI：

  10.1016/0039-128x(76)90010-6

文献信息

• Modified, hydroxy-substituted aromatic structures having cytoprotective activity
  申请人：Washington University

  公开号：US20020103178A1

  公开（公告）日：2002-08-01

  The present invention is directed to modified, hydroxy-bearing aromatic ring structures having cytoprotective activity. More specifically, in a first embodiment the present invention is directed to phenolic compounds, and in particular steriods (e.g., estrogens), wherein a non-fused polycyclic, hydrophobic substituent is attached to the hydroxy-substituted A-ring thereof. The present invention is further directed to a process for conferring cytoprotection to a population of cells involving the administration of the compound.

  本发明涉及具有细胞保护活性的改性、含羟基的芳香环结构。更具体地说，在第一实施例中，本发明涉及酚类化合物，特别是类固醇（例如雌激素），其中非融合的多环、疏水基团附着于其羟基取代的A环上。本发明还涉及一种通过给予化合物的方法，赋予一群细胞细胞保护作用的过程。
• MODIFIED, HYDROXY-SUBSTITUTED AROMATIC STRUCTURES HAVING CYTOPROTECTIVE ACTIVITY
  申请人：Covey F. Douglas

  公开号：US20060009438A2

  公开（公告）日：2006-01-12

  Abstract of the Disclosure The present invention is directed to a process for conferring cytoprotection on a population of cells which comprises administering to that population of cells a compound comprising a hydroxy-substituted aromatic ring structure and a non-fused polycyclic, hydrophobic substituent attached thereto. In particular, the present invention is directed to such a process wherein the administered compound is phenolic, such as a steriod (e.g., estrogen), and has a non-fused polycyclic, hydrophobic substituent attached to the hydroxy-substituted A-ring thereof.

  本发明涉及一种用于给细胞群体提供细胞保护的方法，该方法包括向该细胞群体中投与一种化合物，所述化合物包含一个羟基取代的芳香环结构和一个附着于其上的非融合多环、疏水取代基。特别地，本发明涉及一种这样的方法，其中所投与的化合物为酚类，例如类固醇（例如雌激素），并且具有附着于其羟基取代的A环上的非融合多环、疏水取代基。
• REMEDY FOR HORMONE-DEPENDENT CANCER
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1568381A1

  公开（公告）日：2005-08-31

  A therapeutic agent for a hormone-dependent cancer, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, which may be administered together or separately at an interval, is provided. A method for treating a hormone-dependent cancer, which comprises administering (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy together or separately at an interval, is also provided. A steroid-sulfatase inhibitor which is used in combination with an agent for hormone therapy and/or an agent for chemotherapy, and which is administered together therewith or separately therefrom at an interval, is also provided. A kit for treating a hormone-dependent cancer, which comprises a first component comprising (a) a steroid-sulfatase inhibitor and a second component comprising (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. A pharmaceutical composition, which comprises (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy, is also provided. Further, use of (a) a steroid-sulfatase inhibitor and (b) an agent for hormone therapy and/or an agent for chemotherapy for the manufacture of a therapeutic agent for a hormone-dependent cancer is provided.

  本发明提供了一种激素依赖性癌症的治疗剂，它包括(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂，这两种药物可以一起给药，也可以间隔一段时间分别给药。还提供了一种治疗激素依赖性癌症的方法，该方法包括(a)类固醇-硫酸酯酶抑制剂和(b)激素治疗制剂和/或化疗制剂，它们可以一起给药，也可以间隔一段时间分别给药。还提供了一种类固醇硫酸酯酶抑制剂，该抑制剂与激素治疗剂和/或化疗剂联合使用，并在一定间隔时间内一起或分开给药。还提供了一种用于治疗激素依赖性癌症的试剂盒，它包括由(a)类固醇硫酸酯酶抑制剂组成的第一组分和由(b)激素治疗剂和/或化疗剂组成的第二组分。还提供了一种药物组合物，它包含(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂。此外，还提供了使用(a)类固醇硫酸酯酶抑制剂和(b)激素治疗剂和/或化疗剂制造激素依赖性癌症治疗剂的方法。
• Genotyping human UDP-Glucuronsyltransferase 2B15 (UGT2B15) genes
  申请人：DNA Sciences, Inc.

  公开号：US20030077629A1

  公开（公告）日：2003-04-24

  Genetic polymorphisms are identified in the human UGT2B4, UGT2B7 and UGT2B15 genes that alter UGT2B activity. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for UGT2B substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and in vitro models for drug metabolism.

  在人类 UGT2B4、UGT2B7 和 UGT2B15 基因中发现了改变 UGT2B 活性的基因多态性。包含多态性序列的核酸可用于筛查病人对 UGT2B 底物代谢的改变、潜在的药物相互作用、不良/副作用，以及因环境或职业暴露于毒素而导致的疾病。核酸可用于建立动物、细胞和体外药物代谢模型。
• Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity
  申请人：The University of Chicago

  公开号：US20030099960A1

  公开（公告）日：2003-05-29

  This invention concerns UGT2B7 and its ability to glucuronidate various drugs, including epirubicin. It concerns methods and compositions for determining the level of UGT2B7 activity based on genetic composition, and consequently, allows dosing of UTG2B7-glucuronidated drugs to be improved or optimized based on a patient's level of predicted UGT2B7 activity. It further concerns methods of treatment in which UGT2B7 substrates are administered to patients as part of a treatment regimen.

  本发明涉及 UGT2B7 及其葡萄糖醛酸化各种药物（包括表柔比星）的能力。它涉及根据基因组成确定 UGT2B7 活性水平的方法和组合物，从而可以根据患者的预测 UGT2B7 活性水平改进或优化 UTG2B7-葡萄糖醛酸化药物的剂量。它还涉及将 UGT2B7 底物作为治疗方案的一部分给患者用药的治疗方法。